Evidence map›Paper›PMID 42609039›Full record

ArticleEuropean journal of immunology2026

Growing up as an Immunologist Among Molecular Geneticists.

Klaus Rajewsky

Abstract readHistorical Article
In one paragraph

Article in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Klaus RajewskyImmune Regulation and Cancer, Max-Delbrück-Center For Molecular Medicine in the Helmholtz Association (MDC), Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When I started my independent career as a young medical doctor at the Institute for Genetics in Cologne in 1964, among a faculty of enthusiastic young scientists devoted to the then new field of molecular genetics, my hope to address the basic mysteries of immunology at a similar level was entirely speculative. But the situation changed dramatically over the next three decades, during which we witnessed, and contributed to, the incorporation of basic methods of bacterial and bacteriophage genetics into immunological research, including mutational analysis, ultimately developed into conditional targeted mutagenesis in the mouse. This was accompanied by revolutionary advances in cell separation, the advent of monoclonal antibodies, as well as nucleic acid amplification and sequencing technologies. The present article describes some of the activities of my group in Cologne over these times, focusing on how things got underway in this unique historical context, and along the lines of a lecture given in acceptance of the inaugural EFIS Lifetime Achievement Award in Vienna, 2025.

Indexed as

Allergy and ImmunologyMolecular BiologyAnimalsHistory, 20th CenturyHistory, 21st CenturyHumansMicebiologygeneticsimmunologymolecular biologymolecular genetics

Identifiers

PMID42609039
PMCPMC13482117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.